Calidi Biotherapeutics, Inc. (CLDWW)
- Previous Close
0.0065 - Open
0.0066 - Bid 0.0056 x --
- Ask 0.0100 x --
- Day's Range
0.0055 - 0.0066 - 52 Week Range
0.0055 - 0.0066 - Volume
17,829 - Avg. Volume
-- - Market Cap (intraday)
-- - Beta (5Y Monthly) 1.19
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.
www.calidibio.comRecent News: CLDWW
View More
Compare To: CLDWW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CLDWW
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-112.48%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-23.81M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
9.59M
Total Debt/Equity (mrq)
357.52%
Levered Free Cash Flow (ttm)
-11.21M